ArticleCancer management and research2019

Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways.

Dina S El-Agamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.